
Feb 19, 2025, 10:44
Myeloma Paper of the Day, February 19th, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated with higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS.”
Authors: Doris Hansen et al.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 13:29
Mar 29, 2025, 12:32
Mar 29, 2025, 12:06
Mar 29, 2025, 12:00
Mar 29, 2025, 11:58
Mar 29, 2025, 11:36
Mar 29, 2025, 11:26